# Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

> **NCT01506609** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 294 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Veliparib
- **DRUG:** Carboplatin
- **DRUG:** Temozolomide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01506609
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-23
- **Primary completion:** 2018-12-13
- **Final completion:** 2020-09-02
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506609, "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01506609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*